DSGN Design Therapeutics Inc Gross Profitability Margin

Corporate emblem and logo of Design Therapeutics Inc (DSGN)

Design Therapeutics management relies on external venture financing due to a lack of stable cash flows. The gross profit margin illustrates the results of this strategy, and this metric stands at 0.00. Strong pricing power is driven by the uniqueness of GeneTAC technologies, while diversification through the development of targeted treatments for genetic pathologies minimizes the company's risks.

Return on Gross Profit: Design Therapeutics (DSGN) for 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for designtx.com (DSGN)

- market value and analyst target forecast:
Fundamental valuation:DSGN, Design Therapeutics Inc
Flagship merchandise of Design Therapeutics

For the high-tech genetic medicine business of Design Therapeutics (DSGN), the gross profit margin reflects the efficiency of commercializing innovative molecules relative to their synthesis costs. This ratio measures the portion of revenue minus direct costs, where steady growth confirms the scalability of the therapy, while a sharp decline signals critical expenses and risks to capital.

Main competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|RCKT: Return on Gross Profit|FDMT - Gross Margin|LXEO: Gross Margin|Korro Bio Inc. - Gross Profit Rate|EDIT (editasmedicine.com) - Gross Margin|Gross Profitability SLN|Gross Profitability ProQR Therapeutics NV (PRQR)|Codexis - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability